Department of Pharmacology, Institute of Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin 300100, China.
World J Gastroenterol. 2013 Jul 7;19(25):4053-9. doi: 10.3748/wjg.v19.i25.4053.
To investigate the benefits of probiotics treatment in septic rats.
The septic rats were induced by cecal ligation and puncture. The animals of control, septic model and probiotics treated groups were treated with vehicle and mixed probiotics, respectively. The mixture of probiotics included Bifidobacterium longum, Lactobacillus bulgaricus and Streptococcus thermophilus. We observed the survival of septic rats using different amounts of mixed probiotics. We also detected the bacterial population in ascites and blood of experimental sepsis using cultivation and real-time polymerase chain reaction. The severity of mucosal inflammation in colonic tissues was determined.
Probiotics treatment improved survival of the rats significantly and this effect was dose dependent. The survival rate was 30% for vehicle-treated septic model group. However, 1 and 1/4 doses of probiotics treatment increased survival rate significantly compared with septic model group (80% and 55% vs 30%, P < 0.05). The total viable counts of bacteria in ascites decreased significantly in probiotics treated group compared with septic model group (5.20 ± 0.57 vs 9.81 ± 0.67, P < 0.05). The total positive rate of hemoculture decreased significantly in probiotics treated group compared with septic model group (33.3% vs 100.0%, P < 0.05). The population of Escherichia coli and Staphylococcus aureus in ascites of probiotics treated group were decreased significantly compared with that of septic model group (3.93 ± 0.73 vs 8.80 ± 0.83, P < 0.05; 2.80 ± 1.04 vs 5.39 ± 1.21, P < 0.05). With probiotics treatment, there was a decrease in the scores of inflammatory cell infiltration into the intestinal mucosa in septic animals (1.50 ± 0.25 vs 2.88 ± 0.14, P < 0.01).
Escherichia coli and Staphylococcus aureus may be primary pathogens in septic rats. Probiotics improve survival of septic rats by suppressing these conditioned pathogens.
研究益生菌治疗脓毒症大鼠的益处。
通过盲肠结扎和穿刺诱导脓毒症大鼠。对照组、脓毒症模型组和益生菌治疗组的动物分别用载体和混合益生菌治疗。混合益生菌包括长双歧杆菌、保加利亚乳杆菌和嗜热链球菌。我们观察了不同剂量混合益生菌对脓毒症大鼠的生存情况。我们还通过培养和实时聚合酶链反应检测实验性脓毒症时腹水和血液中的细菌种群。测定结肠组织黏膜炎症的严重程度。
益生菌治疗显著提高了大鼠的存活率，且这种效果呈剂量依赖性。载体治疗的脓毒症模型组的存活率为 30%。然而，1 剂量和 1/4 剂量的益生菌治疗使存活率与脓毒症模型组相比显著增加（80%和 55%比 30%，P<0.05）。与脓毒症模型组相比，益生菌治疗组腹水中的总活菌数显著减少（5.20±0.57 比 9.81±0.67，P<0.05）。与脓毒症模型组相比，益生菌治疗组血培养的总阳性率显著降低（33.3%比 100.0%，P<0.05）。与脓毒症模型组相比，益生菌治疗组腹水中大肠杆菌和金黄色葡萄球菌的数量显著减少（3.93±0.73 比 8.80±0.83，P<0.05；2.80±1.04 比 5.39±1.21，P<0.05）。在给予益生菌治疗后，脓毒症动物的肠黏膜炎症细胞浸润评分降低（1.50±0.25 比 2.88±0.14，P<0.01）。
大肠杆菌和金黄色葡萄球菌可能是脓毒症大鼠的主要病原体。益生菌通过抑制这些条件致病菌来提高脓毒症大鼠的生存率。
